Latest News and Press Releases

WALTHAM, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in...

Business development step enables molecule to move forwardProgram progression will be at no financial risk to RadiusReinforces Radius’ focus on execution of core business WALTHAM, Mass., Oct. 01,...

Target enrollment milestone reached in the Phase 3 EMERALD studyLife cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 24,...

Organizational Change within Finance FunctionCreates Capital, Strategy & Transactions Group WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”)...

WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American...

Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skinTrial success followed by regulatory approval would provide a completely unique drug...

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management...

TYMLOS® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent lifeEnrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males...

WALTHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with...

TYMLOS® U.S. net sales of $50 million, with 22% year over year growth Completion of enrollment in ATOM Phase 3 expected this week Phase 3 Trials: wearABLe and EMERALD remain...